HLA and MICA antibodies: further evidence of their impact on graft loss two years after their detection.
1. At the median post-transplant follow-up (to Ab evaluation) of 51.4 months, the prevalence of anti-HLA and anti-MICA Abs was 21.9% and 19%, respectively. 2. Overall, of the 196 patients included, 124 (63.3%) were negative to all tested Abs, and 72 (36.7%) were positive for: HLA Abs alone = 34; MICA Abs alone = 29; and HLA + MICAAbs = 9. 3. Two years after Ab evaluation, graft survival was significantly lower for patients with HLA + MICA Abs (p = 0.046). 4. The proportion of patients without CNI drugs at the time of Ab evaluation was greater in patients with one Ab and even greater in those with two Abs (HLA + MICA) when compared to patients with a negative Ab determination (p = 0.037).
Morales-Buenrostro
Luis-Eduardo
LE
Nephrology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Rodríguez-Romo
Roxana
R
de Leo
Claudia
C
López
Mayra
M
Pérez-Garrido
Jesús
J
Uribe-Uribe
Norma
N
Alberú
Josefina
J
D005500:Follow-Up Studies; D006085:Graft Survival; D006680:HLA Antigens / Q000276:immunology*; D015395:Histocompatibility Antigens Class I / Q000276:immunology*; D006801:Humans; D007518:Isoantibodies / Q000097:blood*; D007519:Isoantigens / Q000276:immunology; D016030:Kidney Transplantation / Q000276:immunology*; D013997:Time Factors; D017211:Treatment Failure
D006680:HLA Antigens; D015395:Histocompatibility Antigens Class I; D007518:Isoantibodies; D007519:Isoantigens; C099187:MHC class I-related chain A